Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19
- 1 May 2021
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 898, 173988
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Health
This publication has 74 references indexed in Scilit:
- Histone Deacetylase Inhibition Attenuates Transcriptional Activity of Mineralocorticoid Receptor Through Its Acetylation and Prevents Development of HypertensionCirculation Research, 2013
- Histone Deacetylase Inhibition by Sodium Valproate Regulates Polarization of Macrophage SubsetsDNA and Cell Biology, 2012
- Valproic acid reversed pathologic endothelial cell gene expression profile associated with ischemia–reperfusion injury in a swine hemorrhagic shock modelJournal of Vascular Surgery, 2012
- Valproic Acid Attenuates Proteinuria and Kidney InjuryJournal of the American Society of Nephrology, 2011
- Effects of epilepsy and selected antiepileptic drugs on risk of myocardial infarction, stroke, and death in patients with or without previous stroke: a nationwide cohort studyPharmacoepidemiology and Drug Safety, 2011
- Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cellsInternational Journal of Oncology, 2011
- Inhibition of Enveloped Virus Infection of Cultured Cells by Valproic AcidJournal of Virology, 2011
- Inhibition of Histone Deacetylation Blocks Cardiac Hypertrophy Induced by Angiotensin II Infusion and Aortic BandingCirculation, 2006
- Cytokine-Induced Modulation of Cardiac FunctionCirculation Research, 2004
- Pulmonary vascular obstruction in severe ARDS: angiographic alterations after i.v. fibrinolytic therapyAmerican Journal of Roentgenology, 1987